Replies to post #135738 on Biotech Values

[jbog]

Well that's a nice way to start the day. Seems pretty cheap to me, but I'll take it.

[dewophile]

it's become almost a given that companies with platform technologies surrounding Abs get taken over
thanks for turning me on to this company jq

[DewDiligence]

No standalone CC for AMGN-MITI deal, but the buyout will be covered on AMGN's 4Q11 call at 5pm ET today.

[DewDiligence]

AMGN, Astellas ink drug-development/commercialization JV for Japanese market:

http://finance.yahoo.com/news/amgen-astellas-announce-japan-alliance-041200972.html

The JV’s pipeline will consist of the following five AMGN drugs:

• AMG 145 (PCSK9 inhibitor) for CV disease, in phase-3 (phase-2 in Japan)

• AMG 785/Romosozumab for osteoporosis in phase-3

• AMG 102/Rilotumumab for GI cancer in phase-3 (phase-1 in Japan)

• AMG 337 (MET inhibitor) for GI cancer in phase-1

• AMG 103/Blinatumomab (acquired from MITI) for ALL/NHL in phase-2

[jq1234]

AMGN Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia

[via acquisition of Micromet MITI in 2012]


THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow1.

http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1944069